*Purpose: This study aimed to evaluate the effect of influenza vaccine in kidney transplant recipients during the 2017/2018.

*Methods: We retrospectively assessed 136 patients who underwent kidney transplantation (KTx) at our institution between March 2009 and December 2017. All patients had received adequate verbal instructions and provided written informed consent. All patients received tacrolimus or cyclosporine, mycophenolate mofetil, and methylprednisolone to maintain immunosuppression after KTx. Per the criteria of our institution, we administered everolimus to maintain immunosuppression after KTx. We compared the rate of influenza infection between the group treated with one or two shots of influenza vaccine (n=94) and the non-treatment group (n=42) after KTx for 1 year between October 2017 and September 2018.

*Results: Patient characteristics in both groups (Table 1) did not differ significantly between. Influenza infection occurred in the treatment and non-treatment groups at rates of 11.7% (11/94 patients) and 7.1% (3/42 patients), respectively (p=0.590).

*Conclusions: Influenza infection rates were largely similar between patients treated with one or two shots of influenza vaccine and untreated patients, a while after KTx.

« Back to 2019 American Transplant Congress